South Africa began rolling out Lenacapavir, a long-acting injectable HIV prevention medication, on Friday, June 5, 2026 [1].
The introduction of the drug represents a shift in the national strategy to reduce new infections. By offering a long-acting alternative to daily oral medication, the government aims to increase adherence and reach populations in high-burden areas.
Health Minister Aaron Motsoaledi and President Cyril Ramaphosa oversaw the initiative, which focuses on the Mpumalanga province [1]. Stocks of the medication will be delivered to 360 health facilities located within high-burden districts [1].
Lenacapavir is administered as an injection twice yearly [2]. This frequency reduces the burden on patients who previously relied on daily regimens. Officials and health experts said the medication is a breakthrough and a game-changer for the country's public health response [3].
Despite the optimism, some reports indicate that funding shortfalls and limited dose availability could slow the overall impact of the rollout [4]. The government is working to integrate the drug into existing health infrastructure to mitigate these challenges.
Peter Maybarduk said, "Lenacapavir could be transformative" [5].
“South Africa began rolling out Lenacapavir, a long-acting injectable HIV prevention medication, on Friday, June 5, 2026.”
The transition to a twice-yearly injection addresses a primary failure point in HIV prevention: daily pill adherence. While the scale of the rollout in Mpumalanga provides a critical proof-of-concept, the long-term success of the program depends on whether the South African government can secure sustainable funding to expand access beyond the initial 360 facilities.
